title: Myeloprotective effect of a non-toxic indigenous preparation Rasayana in cancer patients receiving chemotherapy and radiation therapy. A pilot study.
abstract: The effect of an indigenous medical preparation--Brahma Rasayana (BR)--on the haemopoetic protection in cancer patients undergoing radio in association with chemotherapy was studied. Administration of BR accelerated the recovery of the haemopoetic system as seen by a rapid rise in total leukocytes. Both lymphocytes and neutrophils were significantly increased by Rasayana treatment. Nadir of WBC was 3633 +/- 120 and 2954 +/- 305 in treated and untreated patients. Nadir of neutrophils was 2830 +/- 964 in treated patients and 1791 +/- 922 in untreated patients. Nadir of lymphocytes remained almost unchanged. Total number of consecutive days of leukopenia, neutropenia and lymphopenia was also significantly reduced after the treatment. Rasayana treatment also made serum lipid peroxidation decrease confirming its capacity of reducing oxidative stress induced by cancer treatment. The use of this non-toxic preparation as an adjuvant in cancer therapy will prove out to be highly beneficial.
authors.affiliation: Amala Cancer Hospital & Research Centre, Amala Nagar, Thrissur, India.
authors.forename: C D
authors.initials: CD
authors.lastname: Joseph
authors.forename: V
authors.initials: V
authors.lastname: Praveenkumar
authors.forename: G
authors.initials: G
authors.lastname: Kuttan
authors.forename: R
authors.initials: R
authors.lastname: Kuttan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects* / Q000528:radiation effects; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000097:blood; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007194:India; D007958:Leukocyte Count / Q000187:drug effects; D007970:Leukopenia / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control*; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D010865:Pilot Projects; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011832:Radiation Injuries / Q000209:etiology / Q000517:prevention & control*; D011878:Radiotherapy / Q000009:adverse effects*
chemical_list: D000975:Antioxidants; D004364:Pharmaceutical Preparations; D010936:Plant Extracts; C403274:brahma rasayana; D005047:Etoposide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D008942:Mitoxantrone; D002945:Cisplatin; D005472:Fluorouracil